ERBB2 and breast carcinoma: Adjuvant trastuzumab (Herceptin) has recently shown an impressive 50% reduction in the risk of early recurrence and a 30% reduction in mortality relative to placebo in women with HER2-positive breast cancer (Romond et al, 2005; Dinh et al, 2007).